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Disruptions of anatomical left-right asymmetry result
in life-threatening heterotaxic birth defects in vital
organs. We performed a small molecule screen
for left-right asymmetry phenotypes in Xenopus
embryos and discovered a pyridine analog, hetero-
taxin, which disrupts both cardiovascular and diges-
tive organ laterality and inhibits TGF-b-dependent
left-right asymmetric gene expression. Heterotaxin
analogs also perturb vascular development, melano-
genesis, cell migration, and adhesion, and indirectly
inhibit the phosphorylation of an intracellular medi-
ator of TGF-b signaling. This combined phenotypic
profile identifies these compounds as a class of
TGF-b signaling inhibitors. Notably, heterotaxin
analogs also possess highly desirable antitumor
properties, inhibiting epithelial-mesenchymal transi-
tion, angiogenesis, and tumor cell proliferation in
mammalian systems. Our results suggest that
assessingmultiple organ, tissue, cellular, andmolec-
ular parameters in awhole organismcontext is a valu-
able strategy for identifying the mechanism of action
of bioactive compounds.
INTRODUCTION
Vertebrate embryos developwith left-right asymmetry, evident in
the asymmetric anatomical positioning of the heart and other
vital organs. Correct asymmetries are essential for the function
of the cardiovascular and digestive systems, and severe malfor-
mations are linked to disruptions of organ laterality. Complete
reversal of normal left-right asymmetries (situs inversus) occurs
in one in 8,500 births (Brueckner, 2007), whereas ‘‘heterotaxia,’’
in which one or more organs deviate from normal by appearing
independently and randomly oriented with respect to left
and right, occurs in one in 10,000 births (Brueckner, 2007).
Heterotaxia is often accompanied by intracardiac defects and
is associated with at least 3% of all congenital heart disease252 Chemistry & Biology 18, 252–263, February 25, 2011 ª2011 Else(Zhu et al., 2006). Also associated with heterotaxia is intestinal
malrotation, which occurs in as many as one in 500 births and
predisposes affected individuals to life-threatening conditions
(Kamal, 2000).
The initial establishment of the left-right axis eventually results
in the expression of genes exclusively on the left side of the
embryo, including the TGF-b family members nodal and lefty,
and the transcription factor Pitx2 (Levin, 2005). Although it has
been demonstrated that situs inversus or heterotaxia can result
if these genes are misexpressed, how such left-right cues are
translated into the asymmetric morphology of developing organs
is poorly understood. Such knowledge is essential for under-
standing the etiology of congenital deformities.
In recent years, whole organism chemical-genetic strategies,
in which pharmacologically well-characterized small molecules
are screened in living embryos for their ability to induce a devel-
opmental phenotype of interest, have been successfully used to
illuminate the mechanisms that establish the initial left-right axis
of the early embryo (e.g., Adams et al., 2006). However, the effi-
cacy of such screening strategies is limited by the availability of
known bioactives capable of exerting specific effects on devel-
oping model organisms. To our knowledge, no discovery-based
screens have been employed to uncover novel compounds that
perturb left-right asymmetric organ morphogenesis. Identifying
novel heterotaxia-inducing small molecules may not only
offer an increased understanding of the molecular etiology of
common birth defects but may also reveal new classes of small
molecules capable of modulating pathways that play important
roles in development and disease.
Unfortunately, uncovering the mechanism of action of a novel
molecule identified in a whole organism or phenotype-based
screen remains a major challenge. Increasingly, multiparameter
phenotypic profiling is being used to categorize small molecules
discovered in high-throughput biochemical assays or cell-based
screens, providing insight into mechanism of action by similari-
ties to reference compounds with known cellular targets (Feng
et al., 2009). However, even compounds identified in multiplex
strategies may still be ineffectual or have unpredictable or toxic
effects in vivo.
Here, we describe an approach to small molecule discovery
that combines the advantages of whole organism screening
and multiplex profiling by generating a multiparameter profilevier Ltd All rights reserved
Figure 1. A Mixture of Pyridine Regioisomers
Causes Heterotaxia in Xenopus
Embryos were treated with (A) DMSO or (B) 200 mM active
pool. (C) Ventral view of organs in intact DMSO control
tadpole. Ventral (D) and left-ventral (E) views of tadpole
in (C) with skin removed, showing the normal asymmetry
(arrowhead, D) of the foregut loop, and the normal coun-
terclockwise rotation of the intestine (curved arrow, E).
(F) Tadpole exposed to active pool. Ventral (G) and right-
ventral (H) view of tadpole in (F) with skin removed,
showing the reversed position (arrowhead, G) of the fore-
gut loop. The intestine is coiling in the normal direction
(curved arrow, H) but is located on the opposite side of
the animal. Ventral views of tadpole exposed to active
pool (I–K) show normal foregut looping (arrowhead, J)
but the intestine coiling in the reversed direction (i.e.,
clockwise; curved arrow, K). (L) Ventral view of heart of
DMSO control, with outflow tract (conus, c) and ventricle
(v) indicated, with the normal direction of cardiac looping
(curved arrow). (M and N) Two examples of heterotaxin-
induced reversed heart looping (curved arrows).
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promise of embryos of the aquatic frog, Xenopus laevis, for small
molecule discovery (e.g., Tomlinson et al., 2009). A unique
feature of Xenopus embryos, not found in other models (e.g.,
zebrafish), is the morphogenesis of their left-right asymmetric
organs, which is highly analogous to humans and easily visible
in situ (Muller et al., 2003). Therefore, we employed Xenopus
embryos in a screen for heterotaxia-inducing compounds and
identified a novel pyridine-based molecule, which we named
‘‘heterotaxin.’’ Further analyses of the in vivo phenotypic profile
of this compound revealed that it elicits multiple TGF-b-depen-
dent phenotypes throughout development and inhibits TGF-b-
dependent intracellular signaling events, identifying it as a new
TGF-b signaling inhibitor. Importantly, heterotaxin analogs also
disrupt invasive phenotypes, angiogenesis, and tumor cell
proliferation in mammalian systems, revealing a new class of
compounds with TGF-b-inhibitory therapeutic potential.Chemistry & Biology 18, 252–263, February 25RESULTS
The Discovery of Heterotaxin (1)
A solid-supported multicomponent cyclotrimeri-
zation reaction (Young et al., 2007) was utilized
to generate a pilot library of 130 novel com-
pounds as 44 pools of regioisomers. We arrayed
X. laevis embryos in individual wells of a 24-well
plate in growth media supplemented with pools
of regioisomers (200 mM). After the embryos
had completed asymmetric morphogenesis, the
morphology of the heart and digestive tract was
assessed in anesthetized tadpoles. All controls,
i.e., untreated or exposed to DMSO alone, had
normal organ asymmetries (Figures 1A, 1C–1E,
and 1L), asdid the embryos in 33/44 (75%) pools.
In our initial screen, 2/44 pools (4.5%)were lethal
at 200 mM, and 8/44 pools (18%) elicitedmultiple
defects (in organ, eye, craniofacial and tail devel-
opment) in exposed embryos. However, onepyridine pool induced clear heterotaxia (heart and/or gut looping
defects) in 100% of the exposed individuals (Figures 1B, 1F–1K,
1M, and 1N). In three repeat trials with embryos derived from
oocytes obtained from different mothers, this pool was effective
at inducing heterotaxia in at least 50% of embryos exposed at
a concentration of 100–200 mM. Overall, 89% (n = 28) of the
embryos in all trials that were exposed to the active regioisomer
pool at 100–200 mM exhibited heterotaxia phenotypes, strongly
implicating one or more regioisomers in this pool as an inhibitor
of a cellular target(s) required for normal left-right asymmetric
organ development.
Identification of the Active Heterotaxia-Inducing
Regioisomer
To facilitate the isolation of the regioisomer responsible for the
observed heterotaxia phenotypes, the solid-phase synthesis
used to generate the original pool was conducted on a 5-fold, 2011 ª2011 Elsevier Ltd All rights reserved 253
Figure 2. Purification, Identification, and Synthesis of Heterotaxin (1)
(A) GC trace of the regioisomers in the active pool.
(B) Active regioisomer (1) after separation (see Supplemental Experimental Procedures), phenotypic assay, and structural assignment.
(C) Regioselective synthetic route toward gram quantities of heterotaxin (1) and analogs (27–31).
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In Vivo Profiling Identifies TGFb Inhibitorslarger scale. A GC trace of the heterotaxia-inducing pool prior to
purification indicated the presence of several different regio-
isomers (Figure 2A). After separating these components by
flash-column chromatography on silica gel, we found that only
the 2,4,6-regioisomer 1 (Figure 2B; GC retention time of 17.17
min) displayed the ability to induce the desired phenotype in
Xenopus embryos (data not shown).
As further confirmation, we exposed embryos of a related
species, Xenopus tropicalis, to this purified component.254 Chemistry & Biology 18, 252–263, February 25, 2011 ª2011 ElseDespite the differences between the X. laevis and X. tropicalis
species in culture temperature (15C versus 24C, respec-
tively), size (1.2 versus 0.7 mm, respectively), and growth
rate (7–8 versus 3–4 days, respectively), the regioisomerically
pure compound induced identical heterotaxic organ
deformities in both the heart and gut as observed in
X. laevis (data not shown). Due to its ‘‘heterotaxia-inducing’’
propensity, we named the purified, active regioisomer
‘‘heterotaxin.’’vier Ltd All rights reserved
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Our original synthesis route toward heterotaxin necessitated
laborious purification of the 2,4,6-regioisomer 1 from a mixed
pool and was, therefore, inefficient for generating the large
(milligram) quantities of heterotaxin required for further charac-
terization. Consequently, we developed a robust, scalable
synthetic approach to heterotaxin, with a sequence of chemical
transformations that provided a completely regioselective
synthesis (Figure 2C).
The synthesis commenced with the condensation of the lithi-
ated trityl-protected propargyl alcohol 2 and commercially avail-
able chlorodiisopropylsilane (3) to afford the silane 4 in 76% yield
(Petit et al., 2003). The silane 4 was then subjected to in situ
bromination by NBS, followed by a subsequent reaction with
propargyl alcohol in the presence of TEA and DMAP in DCM to
afford the silyl ether 5 in 85% over two steps (Petit et al.,
2003). The key step of the synthesis was amicrowave-mediated,
cobalt-catalyzed [2+2+2] cyclotrimerization reaction between
the diyne 5 and propionitrile under open-vessel conditions.
This delivered the pyridine 6 in 98% yield. The silicon tether
allowed for a completely regioselective pyridine formation
(Bols and Skrydstrup, 1995), with the C-N bond being formed
with the substituted sp-carbon center bearing the CH2OTrt
group. The silicon tether was then removed using TBAF in reflux-
ing THF to afford the regioisomerically pure 2,4,6-substituted
pyridine 9 in 99% yield. The alcohol 9 was converted into the
aldehyde 12 in 90% yield using a Swern oxidation. Following
the oxidation, a Wittig reaction was employed to install the C4
chain at the 4-position affording the alkene 15 in amoderate yield
of 78%. Reduction of the double bond in 15 with Pd/C under 1
atm of H2 furnished the pyridine 21 in almost quantitative yield.
The acid-catalyzed deprotection of the trityl group proceeded
smoothly and delivered heterotaxin (1) in 100% yield. This sche-
matic route allowed us to synthesize reasonable (37 mg) quanti-
ties of heterotaxin, and analogs thereof (see below), which we
used to further investigate the mechanism by which it induces
heterotaxia, and to elucidate its mechanism of action.
Multiple Phenotypes Are Induced by Heterotaxin
Heterotaxin perturbs organ laterality, suggesting that it interferes
with global embryonic left-right patterning. Indeed, heterotaxin
perturbs left-right asymmetric gene expression patterns in the
lateral plate mesoderm (LPM). For example, in heterotaxin-
treated embryos, the pattern of the Xenopus nodal homolog,
Xnr-1, is randomized with respect to left and right (Figures 3A–
3D). Although some embryos exhibit normal left-side nodal
expression (36%, n = 28), some show bilateral nodal expression
on both the left and right sides (18%, n = 28), some exhibit
reversed (i.e., right-sided) nodal expression (11%, n = 28), and
some (36%, n = 28) completely lack nodal expression on either
side (Figure 3I). As expected, the expression patterns of the
Xenopus homolog of Pitx2, a transcription factor whose expres-
sion is dependent on nodal activity, is similarly randomized by
exposure to heterotaxin (Figures 3E–3H and 3J). These results
confirm that the organ anomalies induced by heterotaxin repre-
sent bona fide left-right asymmetry defects.
To gain further information about heterotaxin’s mechanism of
action, we carefully assessed heterotaxin-treated embryos
throughout development (Figure 4). Compared to DMSO-treatedChemistry & Biology 18, 252controls (Figure 4A), the melanocytes in heterotaxin-treated
tadpoles exhibit a striking increase in pigmentation and den-
dricity (Figures 4B and 4C), and the number of melanocytes
is reduced by as much as 50% (Figure 4D). Exposure to
heterotaxin also results in dilated vitelline vessels and ventral
hemorrhaging (Figures 4E–4G), suggesting that the compound
perturbs the normal processes of vasculogenesis and/or
angiogenesis.
Finally, in addition to being malrotated, the digestive tracts of
embryos exposed to heterotaxin are wider and shorter than
controls (e.g., see Figures 4E and 4G). The elongation of the
digestive tract is driven by the rearrangements of endoderm cells
within the embryonic gut tube, a process that also facilitates the
formation of the gut lumen and epithelial lining (Reed et al., 2009).
The endoderm cells are initially round but adopt an elongated
shape and remodel their intercellular adhesive junctions as they
move toward the circumference of the gut, intercalating between
each other to forma single layer (Reed et al., 2009). In controls the
resultant simple columnar epithelium can be observed lining the
lumen of the lengthened coils of gut (arrows, Figure 4H). In
contrast, in heterotaxin-treated embryos, the digestive epithe-
lium is still stratified and contains clumps of rounded cells that
have failed to rearrange into a single layer (arrows, Figures 4I
and 4J). These dysmorphic cells block the gut lumen and exhibit
increased intercellular adhesion, as indicated by their intensified
E-cadherin staining (arrows and inset, Figures 4I and 4J). This
unusual morphology suggests that the normal acquisition or
maintenance of migratory cell properties in the embryonic endo-
derm is inhibited in these embryos, preventing the cell rearrange-
ments required for normal gut elongation.
Identifying the Phenocritical Period
for the Effects of Heterotaxin
To determine the phenocritical period in which heterotaxin elicits
each of the above phenotypes, we exposed embryos to hetero-
taxin for limited times (Figure 4K). The expression of left-right
genes in the Xenopus embryo peaks between stages 19 and
26 (Ohi and Wright, 2007). To determine whether heterotaxin
directly affects left-right gene expression or function, we
exposed embryos to heterotaxin at successively later stages of
development beginning at stage 12 (gastrula), 18 (neurula), 26
(late neurula), or 32 (tailbud). The compound can elicit robust
heterotaxic organ phenotypes when applied as late as stage 18,
but will induce heterotaxia only at low frequency at stage 26, and
has no effect on organ asymmetry when applied at stage 32 (Fig-
ure 4K). We then exposed embryos to heterotaxin through stage
26, washed away the compound with multiple rinses in fresh
media, and cultured in the absence of heterotaxin through
organogenesis. We found that even this limited exposure can
disrupt organ asymmetries (Figure 4K), suggesting that hetero-
taxin affects left-right asymmetry between stages 18 and 26,
coinciding with the peak of left-right gene expression.
We used similar exposures to determine the period in which
heterotaxin induces other phenotypes. The melanogenesis
phenotype can be elicited even when heterotaxin is applied as
late as stage 32 (Figure 4K), suggesting that the compound
acts directly on developing melanocyte precursors, which
migrate and differentiate between stage 30 and 40 (Collazo
et al., 1993). Likewise, the effect on gut elongation can also be–263, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 255
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Figure 3. Heterotaxin Perturbs Left-Right Asymmetric Gene Expression Patterns
(A–H) In situ hybridization for nodal (Xnr-1; A–D), and Pitx2 (XPitx2; E–H) genes was performed on DMSO- (A, B, E, and F) and heterotaxin-treated (C, D, G, and H)
embryos. The expression pattern (arrows) is shown for both the left (A, C, E, and G) and right (B, D, F, and H) sides of the embryo (A–D, stage 23; E–H, stage 26).
The frequency of embryos exhibiting left only (Left, black), right only (Right, red), bilateral (gray), or absent (None, white) expression of nodal (I) or Pitx2 (J) is
quantified in the bar graphs.
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(Figure 4K), just prior to when migratory properties are acquired
by endoderm cells in the embryonic gut (Reed et al., 2009),
indicating that heterotaxin exerts a direct effect on these cells.
In contrast the frequency of heterotaxin-induced vasculo-
genesis/angiogenesis defects declines at stage 32 (Figure 4K).
Because the genes that regulate the formation of the vitelline
veins are expressed between stage 18 and 28 (Walmsley et al.,
2002), and the vascular vitelline network is already forming at
stage 30 (Inui and Asashima, 2006), the observed window of
susceptibility to heterotaxin is consistent with the timing of
neovascularization. Overall, these results suggest that multiple
independent phenotypes in heterologous tissues result from het-
erotaxin acting directly and specifically on discrete populations
of embryonic cells at different stages of development.256 Chemistry & Biology 18, 252–263, February 25, 2011 ª2011 ElseStructure-Activity Relationship Studies of Heterotaxin
To further explore heterotaxin’s multifunctionality, we conducted
SAR studies with heterotaxin analogs. Our regioselective route
to heterotaxin (Figure 2C) was purposely designed in a flexible
fashion to enable the introduction of other substituents on the
pyridine ring through the selective replacement of the butyl and
the ethyl side chain with additional functional groups. This
enabled the assembly of a small set of analogs from a common
intermediate. The R1 and R2 groups were selected as methyl,
ethyl, propyl, phenyl, and hydroxymethylene, based on the orig-
inal side chains found in heterotaxin and in order to probe the
size of the putative cellular protein-binding pocket. Thus, we
synthesized substantial quantities of the diyne 5 and used that
to branch out to the synthesis of analogs. The key stepwas again
a cobalt-catalyzed [2+2+2] cyclotrimerization reaction betweenvier Ltd All rights reserved
Figure 4. Heterotaxin Perturbs Melanogen-
esis, Angiogenesis, and Cell Rearrange-
ments
Compared to the round melanocytes seen in
DMSO controls (small arrows, A and C), hetero-
taxin-treated embryos (two different embryos are
shown in B and C) exhibit highly dendritic pigment
cells (large arrows, B and C).
(D) Number of abdominal melanocytes in embryos
exposed to either DMSO, the active pool identified
in the original pilot screen, or different concentra-
tions of purified heterotaxin.
(E–G) Heterotaxin inducesmild (arrows, E and F) to
severe (arrow, G) defects in vasculogenesis
(compare the three different examples in E–G to
DMSO control in A).
(H–J) Immunohistochemical staining for E-cad-
herin (green), laminin (red), and nuclei (blue;
DAPI) on frontal sections (1003) through the gut
tube of embryos treated with DMSO (H, control),
100 mM heterotaxin (I), or 200 mM heterotaxin (J).
A single-layer columnar epithelium lines the diges-
tive tract of the DMSO tadpole (arrows, H; inset at
4003), whereas the cells lining the heterotaxin-
treated gut are round, exhibit high levels of
E-cadherin (green), and have failed to rearrange
into a single layer (arrows, I [inset at 4003], J).
(K) Time course studies reveal the sensitivity of
each phenotype to heterotaxin exposure. Left-
right asymmetry, reversal of heart looping, foregut
looping, and/or intestinal rotation; Vasculo-
genesis/Angiogenesis, hemorrhaging or enlarged
blood vessels; Melanogenesis, decreased number
and increased dendricity of melanocytes; Migra-
tion, perturbed cell rearrangement, indicated by
shortening of the primitive gut tube. ‘‘+’’ indicates
that at least 75% of embryos exhibited the pheno-
type in two or more independent trials; ‘‘+/‘‘ indi-
cates that at least 50% of embryos exhibited the
phenotype in two or more independent trials.
See Figure S1 for a similar phenotypic profile
induced by a known TGF-b inhibitor, SB-505124.
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Figure 5. Synthesis of Additional Hetero-
taxin Analogs from Common Precursors
See Table S1 for SAR analyses of heterotaxin ana-
logs and Supplemental Experimental Procedures.
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nitrile, and benzonitrile), delivering the fused, regioisomerically
pure pyridines 6–8 (R1 = ethyl, butyl, phenyl) in 82%–98% yield.
The silicon tether was then removed using TBAF to afford
the 2,4,6-substituted pyridines 9–11 in 86%–99% yield. The
alcohols 9–11 were converted into the aldehydes 12–14 in
84%–90% yield using the previously employed Swern oxidation,
followed by aWittig reaction with several different alkylphospho-
nium bromides to install different chain lengths at the four posi-
tion in 15–20 (R2 =methyl, propyl, butyl, pentyl). Reduction of the
double bond in 15–20 with Pd/C under 1 atm of H2 furnished the
pyridines 21–26 in almost quantitative yields. The acid-catalyzed
deprotection of the trityl group proceeded smoothly and deliv-
ered the heterotaxin analogs 27–31 in 71%–100% yield.
Two additional analogs were synthesized by deprotection of
the trityl group at different stages of the synthesis (Figure 5).
One deprotection was conducted after removal of the silicon
tether from 9 to afford the diol 32 in 66% yield, and the second
was performed on the alkene 16 to obtain the compound 33 in
63% yield. Installation of different hydrocarbon substituents on
the hydroxyl group of heterotaxin (1) was accomplished by sub-
jecting 1 to deprotonation with NaH, followed by the addition of
the appropriate alkyl halide (methyl, benzyl, and hexyl) to afford
the ethers 34–36 in 42%–86% yield. Finally, the hydroxyl group
of heterotaxin (1) was oxidized to the carboxylic acid 38 by
a two-step oxidation process. First, the aldehyde 37was formed
in moderate yield by oxidation of the alcohol 1 with MnO2, fol-
lowed by a Lindgren oxidation (Stangeland and Sammakia,
2004; Lindgren and Nilsson, 1973) to form the carboxylic acid
38 in 89% yield (Figure 5).
The length of the alkyl chain at the CH2R
2 substituent
was found to be critical for the specific activity of this class of
molecules, with the highest activity being observed for butyl
(heterotaxin, 1) and pentyl (28), whereas ethyl (27), ethylene
(33), hydroxymethylene (32), and hexyl (29) were inactive (or
toxic) (see Table S1 available online). Although the size of the
R1 group does not appear to be critical, as ethyl (heterotaxin, 1),
butyl (31), and phenyl (30) are tolerated, both the butyl (31) and
phenyl (30) substitutions did yield more potent analogs, which
exhibited activity at lower concentrations than the original
heterotaxin molecule (EC50 values = 10 and 50 mM, respectively)
(Table S1). Furthermore, although modifications of the CH2OH
group through methylation (34), oxidation (38), or alkylation (36)258 Chemistry & Biology 18, 252–263, February 25, 2011 ª2011 Elsevier Ltd All rights reservdid not have a major effect on activity,
benzylation (35) produced a very active
compound (EC50 value = 10 mM) (Table
S1). Interestingly, for each analog, the
EC50 for inducing defects in asymmetric
organogenesis was identical to the EC50
for perturbing melanogenesis, vasculo-
genesis/angiogenesis, and/or gut elon-gation, although the severity of each phenotype varied between
analogs (Table S1). These results show that replacing individual
substituents does not isolate the various activities of the
compound, suggesting that the individual phenotypes induced
by heterotaxin are not chemically separable and may result
from perturbation of the same biological target.
Identifying the Cellular Target of Heterotaxin Analogs
Our phenocritical timing studies suggest that heterotaxin
perturbs left-right asymmetry during the stages when asymmet-
rically expressed TGF-b ligands, such as nodal, establish organ
laterality. Therefore, we hypothesized that TGF-b signaling is
inhibited by heterotaxin. Because the above SAR studies indi-
cate that the various phenotypes induced by heterotaxin are
not chemically separable, it is possible that the complete pheno-
typic profile of this compound is attributable to inhibited TGF-b
signaling. This hypothesis is strongly supported by the fact that
exposure to a known small molecule TGF-b signaling inhibitor,
SB505124 (DaCosta Byfield et al., 2004), induced the same
phenotypic profile as our compounds, including heterotaxia,
vasculogenesis and melanogenesis defects, and aberrant
migratory cell properties, within the same phenocritical periods
(Figure S1). Importantly, other signaling pathways that also influ-
ence all four of these developmental processes are unaffected
by heterotaxin (Figure S1).
To test the hypothesis that heterotaxin interferes with TGF-b
signaling, we evaluated the expression of Xantivin, the Xenopus
homolog of lefty, which is normally expressed in the left LPM as
a direct consequence of nodal-type TGF-b signaling (Ho et al.,
2006). Although DMSO-treated control embryos exhibit normal
expression of this target gene in the left LPM, Xantivin could
not be detected in the left or right LPM of heterotaxin-treated
embryos (Figure 6A; Figure S2), strongly suggesting that
nodal-type TGF-b signaling is inhibited by heterotaxin. These
data are consistent with previous reports in which embryos
exposed to a known TGF-b signaling inhibitor failed to express
Xantivin (Ho et al., 2006).
TGF-b receptor activation is conveyed by the phosphorylation
of intracellular mediators, known as Smads, which ultimately
effect transcription (ten Dijke and Hill, 2004). Nodal signaling
occurs primarily via phosphorylation of Smad2; thus, the
level of phosphorylated Smad2 in Xenopus extracts may be
used as an indicator of embryonic nodal-type TGF-b signalinged
Figure 6. Heterotaxin Inhibits TGF-b
Signaling
(A) The frequency of embryos exhibiting left only
(Left, black), right only (Right, red), bilateral
(gray), or absent (None, white) expression of
Xantivin is quantified in the bar graphs. (See Fig-
ure S2 for images of in situ hybridization).
(B) Western blotting of embryos exposed from 10
hpf for 24 hr to DMSO, 200 mM heterotaxin (1),
200 mM phenotypically inactive analog (32),
80 mM active analog (35), and a known nodal
signaling inhibitor (SB-505124; 50 mM). Although
unmodified Smad2 is detected under all condi-
tions, phosphorylated Smad2 (pSmad2) is only
detected in the presence of DMSO or the inactive
heterotaxin analog 32 (albeit at reduced levels).
ERK is total protein control.
(C) Western blotting of embryos exposed to
DMSO, 1, 32, 35 and the BMP signaling inhibitor,
dorsomorphin (DM; 50 mM). BMP-specific
Smad1/4/5 levels are unaffected by heterotaxin
analogs.
(D) Activin-induced elongation in Xenopus animal
cap explants is inhibited by active heterotaxin
analogs 1 and 35, but not DMSO or analog 32.
The box plot shows that activin-induced length-
ening (results pooled from two identical trials) is
inhibited significantly only by compounds 1 and
35, as calculated by one-way ANOVA (*p < 0.05).
Error bars indicate the first through third interquar-
tile range of the measured lengths.
(E) Western blotting of A549 cells exposed to
10 ng/ml TGF-b1 and DMSO, 100–200 mM 1, 32,
35, or 10 mM SB-431542 for 48 hr. TGF-b1-
induced upregulation of Vimentin and Snail is
inhibited by analogs 1 and 35, but not DMSO or
analog 32. GAPDH is total protein control.
(F) Western blotting of A549 cells exposed to
10 ng/ml TGF-b1 and DMSO, 100–200 mM 1, 32,
35, or 10 mM SB-431542 for 1 hr. TGF-b1-induced
phosphorylation of Smad2 is unaffected by
heterotaxin analogs. GAPDH controls for total
protein.
See Figure S2 for effect of 1 on non-Smad-depen-
dent TGF-b signaling via PI3K/Akt.
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Smad2 is unaffected by exposure to DMSO (Figure 6B, lane 1).
However, Smad2 phosphorylation is abolished in embryos
exposed to heterotaxin (1) (Figure 6B, lane 2), or to the more
potent heterotaxin analog 35 (Figure 6B, lane 4), but is onlymildly
downregulated by exposure to the phenotypically inactive
heterotaxin analog 32 (Figure 6B, lane 3). The inhibition of
Smad2 phosphorylation by heterotaxin is comparable to that
induced by SB-505124 (Figure 6B, lane 5). Importantly, the level
of phosphorylated Smad1/5/8, which indicates signaling via
other TGF-b superfamily ligands such as BMP, remains unaf-
fected by heterotaxin analogs (Figure 6C); thus, the effect of
heterotaxin is specific for Smad2-dependent TGF-b signaling.
A unique advantage of amphibian embryos is the ability to
culture specific embryonic tissues ex vivo in order to isolate
the effects of exogenous growth factors on cell behavior. It is
well established that the addition of the Smad2-mediated
TGF-b ligand activin to Xenopus ‘‘animal cap’’ explants can elicit
concentration-dependent elongation in a tissue that wouldChemistry & Biology 18, 252otherwise remain naive to TGF-b signals and fail to elongate at
all (Green, 1999). We employed this assay to quantify the degree
to which heterotaxin analogs interfere with TGF-b-ligand-depen-
dent signaling. In contrast to DMSO or the inactive analog 32,
heterotaxin (1) and the potent analog 35 significantly inhibit acti-
vin-induced animal cap elongation (Figure 6D); thus, heterotaxin
analogs inhibit activin-dependent activity in Xenopus.
To determine if heterotaxin analogs inhibit the activity of other
TGF-b ligands, we assessed their activity in human cell culture.
A549 cells undergo an epithelial-mesenchymal transition in
response to TGF-b1 (Kim et al., 2007), as indicated by the upre-
gulation of mesenchymal markers such as Snail and Vimentin
(Figure 6E, compare lanes 1–2). Heterotaxin (1) and the potent
analog 35 inhibit the upregulation of these markers (Figure 6E,
lanes 4–7), whereas DMSO or the inactive analog 32 has no
effect (Figure 6E, lanes 3 and 8–9); thus, heterotaxin analogs
inhibit TGF-b1-dependent activity in human cells.
To determine if heterotaxin compounds directly affect ligand-
dependent Smad2 phosphorylation, we assessed levels of–263, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 259
Figure 7. Heterotaxin Inhibits Angiogenesis
in Human Cells
HUVECs form tubes when cultured in the pres-
ence of media alone (A), DMSO (B), unsubstituted
pyridine (C), or the inactive heterotaxin analog 32
(J). In contrast, HUVECs cultured in the presence
of a known anti-angiogenic agent, sulforaphane
(D) (Bertl et al., 2006), are unable to form tubes.
Although the original heterotaxin molecule 1 (F)
exhibits only very mild anti-angiogenic effects in
this assay (at 6 hr), the other active heterotaxin
analogs 36 (G), 35 (H), and 30 (I) have obvious
concentration-dependent anti-angiogenic proper-
ties comparable to a known TGF-b signaling
inhibitor (E, SB-505124). Cells were stained with
Calcein AM to confirm viability.
See Figure S3 for effect of analog 30 on tumor cell
growth.
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induction (Figure 6F). Compared to the effect of SB431542,
a known TGF-b type I receptor inhibitor (Inman et al., 2002),
TGF-b1-induced Smad2 phosphorylation remained relatively
unaffected by our compounds in this time frame, suggesting
that the effect of heterotaxin on Smad2 phosphorylation in vivo
may not involve direct inhibition of TGF-b receptors or may
inhibit a non-Smad-dependent TGF-b signaling pathway (Zhang,
2009).
We tested the latter possibility by assessing the effect of
heterotaxin on TGF-b1-induced activation of phosphatidylinosi-
tol 3-kinase (PI3K), as well as mitogen-activated protein kinases
(MAPKs), including p38, c-Jun amino-terminal kinase (JNK),
and extracellular signal-regulated kinase (ERK). Although the
activation of most of these non-Smad pathways was not sup-260 Chemistry & Biology 18, 252–263, February 25, 2011 ª2011 Elsevier Ltd All rights reservpressed by our compound (data not
shown), TGF-b1-induced activation of
PI3K (1 hr induction), as indicated by the
levels of phosphorylated Akt (Ser-473)
(Figure S2E, lanes 1–2), was inhibited by
heterotaxin (1) (Figure S2E, lanes 4–5),
whereas DMSO and the inactive analog
32 had no effect (Figure S2E, lanes 3
and 6). Taken together, these results
indicate that 2,4,6-substituted pyridines
function as both indirect (Smad2 depen-
dent) and direct (non-Smad dependent)
TGF-b signaling inhibitors.
Heterotaxin Analogs Exhibit
Anti-Angiogenic Properties
in Mammalian Cells
In addition to development, the TGF-b
pathway also plays a multiphasic role in
tumor progression. Although early in
tumorigenesis TGF-b is tumor suppres-
sive (Jakowlew, 2006), later tumor
cells are resistant to TGF-b-mediated
growth inhibition, and upregulation of
TGF-b facilitates metastatic invasion,promoting cell migration and epithelial-to-mesenchymal transi-
tion (Yingling et al., 2004; Tian et al., 2003), as well as new blood
vessel growth and angiogenesis (ten Dijke and Arthur, 2007),
crucial requirements for tumor growth and metastasis.
Therefore, TGF-b signaling inhibitors, like heterotaxin and its
analogs, may be useful for blocking the tumor-promoting effects
of TGF-b. Because our compounds inhibit vascular development
in vivo, we assessed their anti-angiogenic potential in a mamma-
lian system (Figure 7). The human umbilical vein endothelial cell
(HUVEC) assay provides a visual readout of the ability of exoge-
nous factors to inhibit the formation of microcapillary tubes (e.g.,
Figure 7D). Compared to solvent or pyridine controls (Figures 7B
and 7C), the heterotaxin analogs that inhibited vascular develop-
ment in Xenopus (e.g., 1, 30, 35, 36) (see Table S1) were also able
to inhibit tube formation (Figures 7F–7I) in HUVEC cultures.ed
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receptor inhibitor (Figure 7E). However, whereas TGF-b receptor
inhibitors can also block the growth-inhibitory effects of TGF-b
(e.g., SB-431542; Halder et al. [2005]), promoting tumorigenesis,
heterotaxin analogs appear not to have this limitation. In fact,
compound 30 not only inhibits angiogenesis (Figure 7I) but also
significantly inhibits growth in several mammalian tumor cell
lines (Figure S3). Thus, 2,4,6-substituted pyridine analogs may
be broadly applicable in the development of anti-angiogenic
antitumor compounds in mammalian systems.
DISCUSSION
Amulti-phenotype-based whole organism screen of small mole-
cules in X. laevis embryos identified a novel class of pyridines
with TGF-b inhibitory activity. Our data have implications for
understanding the role of the TGF-b pathway in the development
of left-right asymmetry, gutmorphogenesis, melanogenesis, and
vascular development, and for the employment of heterotaxin
analogs in the development of TGF-b inhibitory lead compounds
with therapeutic potential.
Heterotaxin and the Role of TGF-b in Left-Right
Asymmetry, Melanogenesis, Vasculogenesis,
and Gut Development
Our results validate our phenotypic screen for heterotaxia
because TGF-b ligands are well known to play an evolutionarily
conserved role in the development of left-right asymmetry (Whit-
man and Mercola, 2001). Moreover, in addition to left-right
patterning, TGF-b signaling has also been implicated in the other
biological processes disrupted by heterotaxin. For example,
TGF-b signaling is required for the assembly of the embryonic
vasculature (ten Dijke and Arthur, 2007), the establishment of
vessel wall integrity (Pepper, 1997), and the regulation of
vascular homeostasis (Bertolino et al., 2005). As might be pre-
dicted to occur in the presence of a TGF-b inhibitor, heterotaxin
dramatically impairs angiogenesis both in vivo and in vitro.
Because in vitro tube formation may also be influenced by other
factors, confirmation of a direct effect of heterotaxin on human
angiogenesis must await further studies in mammalian models.
Nonetheless, the similarity of the anti-angiogenic activity profiles
of heterotaxin analogs in both frog embryos and human cells
suggests that these compounds could have broader
applicability.
In addition, TGF-b signaling normally increases melanocyte
precursor proliferation (Kawakami et al., 2002) but inhibits
melanogenic differentiation (Kim et al., 2004). Consistent with
the expected outcome of inhibiting TGF-b signaling, heterotaxin
exposure during melanocyte precursor migration and differenti-
ation results in decreased melanocyte number but increased
dendricity. Because nodal is expressed in aggressive mela-
nomas, which reacquire melanocyte precursor-like properties,
heterotaxin analogs may be promising in the development of
differentiation-based anti-melanoma therapies (Hendrix et al.,
2007).
Finally, in multiple contexts, TGF-b signaling induces cell
motility and decreased E-cadherin-mediated intercellular adhe-
sion in cells undergoing epithelial-to-mesenchymal transitions
(Xu et al., 2009). In the developing gut, heterotaxin inhibits migra-Chemistry & Biology 18, 252tory cell morphology and behavior, and concomitantly increases
E-cadherin levels, as might be predicted for an inhibitor of TGF-b
signaling. The effect of heterotaxin on gut morphogenesis
provides a novel inroad for investigating the role of TGF-b
signaling in the poorly understood processes of gut elongation
and rotation.
The Cellular Target of Heterotaxin
Heterotaxin compounds disrupt Smad2 phosphorylation in vivo,
although this is not a direct effect. Possiblemechanismsof action
of heterotaxin and its analogs include inhibiting the synthesis,
secretion, or processing of TGF-b receptors or ligands. Alterna-
tively, these compounds could be influencing non-Smad-depen-
dent pathways downstream of TGF-b receptors. Indeed, we
found that heterotaxin directly inhibits TGF-b-induced PI3K
activity. Althoughactivationof PI3KbyTGF-b requires the activity
of TGF-b receptors, the molecular interactions underlying the
activation of non-Smad-dependent TGF-b signaling events are
extremely complex andcontext dependent (Zhang, 2009). There-
fore, further investigations of the role of PI3K-mediated TGF-b
signaling during Xenopus development will be required before
the cellular target(s) of 2,4,6-substituted pyridines can be fully
resolved. Nonetheless, because non-Smad-dependent TGF-b
pathways are frequently involved in activating the pro-oncogenic
effects of TGF-b signaling during tumor progression, e.g., PI3K-
Akt signaling is required for Smad-dependent transcriptional
responses as well as tumor cell migration (Bakin et al., 2000),
our results raise the exciting possibility that heterotaxin
compoundsmight be able to selectively target TGF-b-dependent
tumor-promoting outcomes without also blocking the tumor-
suppressive effects of TGF-b. This property could be important
for selectively controlling distinct TGF-b responses in different
therapeutic contexts.
Heterotaxin Analogs as Therapeutic Agents
Because of their important roles in tumorigenesis, TGF-b
pathway components are excellent chemotherapeutic targets,
although compounds that can appropriately modulate this
multifunctional pathway in vivo are still in development. We
discovered compounds that specifically inhibit nodal-dependent
gene expression and multiple TGF-b-dependent biological
processes in a whole vertebrate embryo, including neovascula-
rization and migratory behavior. In addition, heterotaxin analogs
inhibit TGF-b-induced epithelial-mesenchymal transition and
angiogenesis in human cells, while inhibiting the growth of
multiple mammalian tumor cell lines. Thus, heterotaxin analogs
exhibit highly desirable biological activity and may be valuable
in the development of TGF-b-inhibitory chemotherapeutics for
blocking tumor proliferation and/or metastasis.
SIGNIFICANCE
In the developing embryo, a myriad of cellular processes
form organs in a dynamic and complex three-dimensional
milieu. In disease states these same processes occur
inappropriately in equally complicated adult environments.
Identifying small molecules that can predictably modulate
cellular processes in their multifarious biological contexts
is imperative for the discovery of effective drugs and stem–263, February 25, 2011 ª2011 Elsevier Ltd All rights reserved 261
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identified in target-based biochemical or simplified cell-
based assays because such assays are amenable to high-
throughput screening; consequently, the in vivo effects of
such compounds are often unpredictable. Although multi-
plexed profiling can provide important information about
potential toxicity andmechanism of action, such knowledge
is not necessarily predictive of efficacy in vivo. Moreover,
even when a compound has been identified in a whole
organism phenotype-based screen, there is as yet, to our
knowledge, no reliable or systematic way to determine its
cellular target(s).
We have shown that a whole organism multi-phenotype
profiling strategy can be used to both identify compounds
capable of modulating important biological processes
in vivo and to infer mechanism of action. Using a combina-
tion of independent tissue-level developmental phenotypes,
immunohistochemical analyses, gene expression patterns,
tissue culture, and biochemical assays, we discovered
a class of TGF-b signaling inhibitors. Remarkably, these
compounds also elicit TGF-b-dependent phenotypes in
human cells that mirror their activity profiles in vivo, sug-
gesting that they may be valuable in the development of
therapeutic agents to inhibit pathologic conditions medi-
ated by excess TGF-b signaling (e.g., metastasis, fibrosis).
Our discovery suggests that multi-phenotype profiling in
whole organisms is a powerful strategy for identifying the
pathway-level mechanism of action of small molecules.
EXPERIMENTAL PROCEDURES
Embryo Screening and Animal Caps
Experiments involving live animals were performed in accordance with
national regulations, and approved by the NC State University Institutional
Animal Care and Use Committee. X. laevis embryos were obtained by
in vitro fertilization, de-jellied with 2% cysteine-HCl (pH 7.8–8.1), sorted to
eliminate anomalous individuals, and cultured in 0.13 MMR at 15C–22C
(Sive et al., 1998). Staging was according to Nieuwkoop and Faber (1994).
Stock solutions were prepared in DMSO (20 mM). For the screen, approxi-
mately 130 compounds were diluted to 200 mM in 2 ml 0.13MMR in a 24-well
plate; 1% DMSO was used as a solvent control. Four embryos were exposed
in eachwell starting at10 hr after fertilization. Organs were evaluated in anes-
thetized tadpoles (0.05% MS-222) when controls reached stage 44–46.
Animal caps were dissected (Green, 1999) and cultured in 5 ng/ml human
activin A (R&D Systems), or activin plus DMSO, 200 mM 1, 32, or 35 for 2 hr.
Caps were then cultured 8 hr in 0.753 MMR + gentamycin (Sive et al.,
1998). Final explant lengths were calculated using Photoshop CS2 (Measure
tool). The significance of decreased elongation was determined by one-way
ANOVA between groups.
In Situ Hybridization and Immunohistochemistry
Embryoswerefixedat st23/26 inMEMFA(Siveetal., 1998).Digoxigenin-labeled
riboprobes for Xnr-1, Xantivin (gift of C. Wright), and XPitx2c were synthesized
from linearized plasmids (Muller et al., 2003). In situ hybridization was as
described (Lipscomb et al., 2006). St 44 embryos were fixed for immunohisto-
chemistry and processed for cryosectioning (Fagotto and Gumbiner, 1994).
Staining was performed using anti-E-cadherin (DSHB; 5D3 at 1:200) and anti-
laminin (Sigma; L9393 at 1:200) primary antibodies and Alexa-conjugated
secondary antibodies (Invitrogen; 1:2000), as described (Reed et al., 2009).
Tube Formation
HUVECs were cultured in Media 200PRF with LSGS supplement (Invitrogen).
The Cultrex In Vitro Angiogenesis Assay Tube Formation Kit (Trevigen) was262 Chemistry & Biology 18, 252–263, February 25, 2011 ª2011 Elseused according tomanufacturer’s protocol. Subconfluent HUVECs at passage
5 (80%confluent) were incubated with 2 mMCalcein AM for 30min at 37C to
allow for fluorescent monitoring of cell viability and tube formation. Cells were
treated with DMSO, sulforaphane, or heterotaxin analogs/SB-505124 at the
time of seeding. Tube formation was assessed 6 hr after treatment.
Western Blotting
St 10 embryos were exposed to DMSO, heterotaxin analogs, SB-505124,
or dorsomorphin for 24 hr. Ten embryos from each treatment were pelleted,
resuspended in 100 ml lysis buffer (20 mM Tris [pH 7.4], 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM
b-glycerophosphate, 1 mM sodium vanadate, 1 mg/ml leupeptin), and lysed
by mechanical disruption, followed by freeze-thaw cycles. Approximately
20 mg of each cleared lysate was run on a 10% NuPAGE Bis-Tris gel and
then transferred to a PVDF membrane. Membranes were blocked for 1 hr in
TBST (20 mM Tris [pH 7.6], 136 mM NaCl, 0.1% Tween 20) + 5% nonfat dry
milk, and incubated overnight at 4C with primary antibodies (see below).
Membranes were washed four times in TBST, incubated for 2 hr in TBST+
5% nonfat dry milk and HRP-conjugated donkey anti-rabbit IgG (Upstate),
washed three to four times in TBST, then visualized using chemiluminescence
with SuperSignal West Pico (Pierce).
A549 cells (ATCC) were maintained in DMEMwith antibiotics and 10% FBS.
Cells were starved overnight in DMEM with 1% FBS and incubated with
DMSO, heterotaxin analogs, or SB-431542 in DMEM with 10% FBS for
30 min before treatment with rhTGFb1 (R&D Systems) for 1–48 hr. Whole-
cell lysates were prepared in RIPA lysis buffer (Pierce) with complete Mini
EDTA Protease Inhibitor and Phos-STOP (Roche) and sonication. Approxi-
mately 40 mg of each cleared lysate was run on a 4%–12% NuPAGE Bis-Tris
gel and then transferred to a nitrocellulose membrane before blocking and
antibody staining as above. Autoradiography bands were scanned and quan-
titated with ImageJ freeware. The integrated optical density of each band was
normalized to GAPDH or b-actin and the fold change determined by dividing
each normalized value by the lowest normalized sample value.
Primary antibodies used were Smad2, phospho-Smad2, phospho-
Smad1/5/8, phospho-p38, Erk, phospho-Erk, phospho-SAPK/JNK, phos-
pho-Akt (Ser473), and Snail from Cell Signaling Technology, and Vimentin,
b-actin, and GAPDH from Santa Cruz Biotechnology.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
doi:10.1016/j.chembiol.2010.12.008.
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